Shenzhen Xzing Technology Co. Ltd. received marketing approval from China’s NMPA for its Endofresh disposable electronic colonoscope. The disposable colonoscope provides images with 1920 x 1080 pixels, which helps with diagnosis. It is equipped with auxiliary water and a lens-washing function to make sure of clear vision throughout endoscopy. It also allows users to insert endoscopic accessories at any bending angle no more than 210 degrees.
Camera pills were never quite like this. Developed by Vibrant Gastro Inc. for people suffering from chronic idiopathic constipation (CIC) the Vibrant system capsule is designed to travel deep into the gut and vibrate, augmenting the natural mechanisms of the body that govern bowel function.
Poor phase II top-line data for Immunic Inc.’s lead candidate, vidofludimus calcium (IMU-838) hammered the stock June 2 as the study of the selective oral DHODH inhibitor missed its primary endpoint of clinical remission in treating moderate to severe ulcerative colitis. The failure means Immunic won’t pursue a phase III study on its own in the indication, but it won’t affect the company’s planned phase III studies of IMU-838 in treating relapsing multiple sclerosis (MS) and a phase II in treating progressive MS.
New and updated preclinical and clinical data presented by biopharma firms at Digestive Disease Week 2022, including: Ardelyx, Ferring, Ironwood, Janssen, Phathom, Rebiotix, Redhill, Second Genome.
Perianal fistulas in Crohn's disease represent a severe complication of the disease. Researchers used a recently established Crohn's perianal fistula rat model to test a novel and proprietary biodegradable nanofiber-hydrogel composite (NHC) loaded with rat adipose-derived stem cells (ADSCs).
Unveiling further positive data for SER-109 in preventing recurrent Clostridium difficile infection at Digestive Disease Week (DDW) over the weekend, Seres Therapeutics Inc. reiterated plans to file a BLA with the U.S. FDA in mid-2022. Should the FDA accept the application and grant priority review – SER-109 has breakthrough and orphan status – the medicine could be the first microbiome-based therapy to reach the market.
RSS
